Discovery opens door for more targeted treatments for cancer patients

NewsGuard 100/100 Score

Cancer patients could one day experience fewer side effects from chemotherapy following a discovery that opens the door for more targeted treatments.

Researchers have identified a possible way of treating tumours that would see doctors place harmless metal implants at the cancer site.

The discovery could make treatment more targeted than existing therapies, avoiding unwanted side effects, such as hair loss, tiredness and nausea. These occur when chemotherapy drugs carried in the blood kill healthy cells as well as cancer cells.

The scientists found that they could alter the chemical composition of commonly used chemotherapy drugs so that they only become active when they come into contact with a metal called palladium.

Researchers hope that by implanting small devices coated with palladium into patients' tumours, the drugs would become activated only where they are needed, causing minimal damage to the rest of the body.

The scientists reported their discovery today in the journal Nature Communications but the approach will first need to be tested in animals before it can be studied in patients.

The research was led by scientists from the Edinburgh Cancer Research UK Centre at the MRC Institute of Genetics and Molecular Medicine, the University of Edinburgh.

Dr Asier Unciti-Broceta, who led the study, said: "It will be several years before we're able to start treating patients but we're hopeful that this approach will lead to better tolerated cancer therapies in the future."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MONET: New AI tool enhances medical imaging with deep learning and text analysis